The biology of chronic myelogenous leukemia progression: who, what, where, and why?

  • Jerald P Radich
  • Published 2011 in Hematology/oncology clinics of North America


Before the days of transplantation and tyrosine kinase inhibitor therapy, all cases of chronic myelogenous leukemia would inevitably proceed from chronic phase through accelerated and blast crisis, implying that there is a program of progression set in motion by unopposed BCR-ABL activity. Since then, much work has identified a plethora of genetic changes… (More)
DOI: 10.1016/j.hoc.2011.09.002


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics